BR112013000296A2 - agentes terapêuticos 976 - Google Patents

agentes terapêuticos 976

Info

Publication number
BR112013000296A2
BR112013000296A2 BR112013000296A BR112013000296A BR112013000296A2 BR 112013000296 A2 BR112013000296 A2 BR 112013000296A2 BR 112013000296 A BR112013000296 A BR 112013000296A BR 112013000296 A BR112013000296 A BR 112013000296A BR 112013000296 A2 BR112013000296 A2 BR 112013000296A2
Authority
BR
Brazil
Prior art keywords
therapeutic agents
azetidinyl
compound
prophylaxis
disease
Prior art date
Application number
BR112013000296A
Other languages
English (en)
Inventor
Carls Hogner Anders
Christian Ingvar Löfberg Björn
Li Lanna
Fredenwall Marlene
Oskar Sverker Von Unge Per
Anderw Judkins Robert
Doris Margit Bökman-Winiwarter Susanne
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013000296(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112013000296A2 publication Critical patent/BR112013000296A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

agentes terapêuticos 976. a presente invenção refere-se a ocmpostos de azetidinila da fórmula i, como descritas neste pedido, as composições farmacêuticas compreendendo um composto de azetidinila, e um método de uso de um composto de azetidinila no tratamento ou profilaxia de uma doença ou a condição relacionada ao hormônio concentrador de melanina.
BR112013000296A 2010-07-06 2011-07-04 agentes terapêuticos 976 BR112013000296A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06
PCT/GB2011/051256 WO2012004588A2 (en) 2010-07-06 2011-07-04 Therapeutic agents 976

Publications (1)

Publication Number Publication Date
BR112013000296A2 true BR112013000296A2 (pt) 2019-09-24

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000296A BR112013000296A2 (pt) 2010-07-06 2011-07-04 agentes terapêuticos 976

Country Status (26)

Country Link
US (1) US8546375B2 (pt)
EP (1) EP2590969B1 (pt)
JP (1) JP5827683B2 (pt)
KR (1) KR20130041177A (pt)
CN (1) CN103209979B (pt)
AR (1) AR082113A1 (pt)
AU (1) AU2011275547B2 (pt)
BR (1) BR112013000296A2 (pt)
CA (1) CA2802832A1 (pt)
CL (1) CL2013000027A1 (pt)
CR (1) CR20130005A (pt)
CU (1) CU20130004A7 (pt)
DO (1) DOP2013000004A (pt)
EA (1) EA201291384A1 (pt)
EC (1) ECSP13012369A (pt)
ES (1) ES2527466T3 (pt)
GT (1) GT201300006A (pt)
HK (1) HK1182712A1 (pt)
MX (1) MX2012015102A (pt)
NI (1) NI201200196A (pt)
PE (1) PE20130781A1 (pt)
SA (1) SA111320581B1 (pt)
SG (1) SG186275A1 (pt)
TW (1) TW201206916A (pt)
UY (1) UY33487A (pt)
WO (1) WO2012004588A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
WO1993013083A1 (en) 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
US7541477B2 (en) 2002-07-30 2009-06-02 Banyu Pharmaceutical Co., Ltd. Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
DE602005014786D1 (de) 2004-07-26 2009-07-16 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor-wirkstoffe, deren herstellung und therapeutische verwendung
JP5057982B2 (ja) 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体阻害剤、製造及び治療的使用
EP1828177B1 (en) 2004-12-17 2008-08-13 Eli Lilly And Company Novel mch receptor antagonists
WO2006068594A1 (en) 2004-12-21 2006-06-29 Astrazeneca Ab HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
WO2006130075A1 (en) 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
US20080221107A1 (en) 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
WO2007078251A1 (en) 2006-01-06 2007-07-12 Astrazeneca Ab Compounds
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
JP5290192B2 (ja) 2006-12-05 2013-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｃｈ−１に媒介される疾患における使用のための新規な置換されたジアザ−スピロ−ピリジノン誘導体
EA015559B1 (ru) * 2006-12-14 2011-08-30 Эли Лилли Энд Компани ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
WO2008131103A2 (en) 2007-04-17 2008-10-30 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
CN101790532B (zh) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
ATE519738T1 (de) 2007-08-22 2011-08-15 Hoffmann La Roche Pyrrolidinarylether als nk3-rezeptorantagonisten
MX2010003949A (es) * 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
US8691804B2 (en) * 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
JP5535310B2 (ja) 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers

Also Published As

Publication number Publication date
AR082113A1 (es) 2012-11-14
ES2527466T3 (es) 2015-01-26
DOP2013000004A (es) 2013-04-30
CN103209979B (zh) 2016-02-10
CA2802832A1 (en) 2012-01-12
ECSP13012369A (es) 2013-01-31
CN103209979A (zh) 2013-07-17
NI201200196A (es) 2013-10-16
EP2590969A2 (en) 2013-05-15
CL2013000027A1 (es) 2013-03-08
KR20130041177A (ko) 2013-04-24
MX2012015102A (es) 2013-05-01
AU2011275547B2 (en) 2015-10-29
TW201206916A (en) 2012-02-16
EP2590969B1 (en) 2014-10-15
SA111320581B1 (ar) 2014-06-17
AU2011275547A1 (en) 2013-02-07
UY33487A (es) 2012-02-29
JP2013535413A (ja) 2013-09-12
WO2012004588A2 (en) 2012-01-12
CR20130005A (es) 2013-04-17
WO2012004588A3 (en) 2012-08-09
CU20130004A7 (es) 2013-05-31
SG186275A1 (en) 2013-01-30
EA201291384A1 (ru) 2013-07-30
US20120010189A1 (en) 2012-01-12
HK1182712A1 (en) 2013-12-06
PE20130781A1 (es) 2013-07-20
US8546375B2 (en) 2013-10-01
JP5827683B2 (ja) 2015-12-02
GT201300006A (es) 2014-11-06

Similar Documents

Publication Publication Date Title
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
MX2011009847A (es) Agentes antihelminticos y su uso.
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
GB2511685A (en) Muscarinic m1 receptor agonists
EA201390198A1 (ru) Гетероциклическое соединение
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX340985B (es) Compuestos de n-heteroarilo.
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
EA201590562A1 (ru) Бензамиды
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2011013869A (es) Agentes antihelminticos y su uso.
BRPI0917245B8 (pt) compostos derivados de isoquinolinona e sua composição farmacêutica
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112013000296A2 (pt) agentes terapêuticos 976
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.